Is pregabalin efficacious for pain management in fibromyalgia patients inspite of comorbid osteoarthritis?
Fibromyalgia patients frequently suffer from comorbid states like osteoarthritis (OA). Therefore, a pooled exploratory analysis of three randomized placebo-controlled clinical trials was employed so as to gain knowledge about how FM patients with comorbid OA respond to recommended therapies (such as pregabalin) could aid their treatment.
For this, the patients were divided into those with and without comorbid OA. The fluctuations in changes in least squares (LS) mean pain score at endpoint (assessed by 0–10 numeric rating scale, controlled for baseline pain score) with pregabalin (300 mg/day and 450 mg/day) vs placebo was assessed. Evaluation of changes in Patient Global Impression of Change (PGIC) responders and Fibromyalgia Impact Questionnaire (FIQ) total score was also done.
The outcomes showed that pregabalin 450 mg/day significantly improved the LS mean (95% confidence interval) difference in pain score vs placebo in patients with (0.99 [0.44, 1.55], P < 0.001), and without (0.64 [0.39, 0.89], P < 0.001) OA. There were advancements in PGIC and FIQ total score in patients with and without comorbid OA. This data could furnish guidance to healthcare professionals treating these patients.